Early diagnosis is key to treating PKU, a rare genetic disorder that results in an amino acid imbalance in the body. According to research or other evidence, the following self-care steps may be helpful:
These recommendations are not comprehensive and are not intended to replace the advice of your doctor or pharmacist. Continue reading the full phenylketonuria article for more in-depth, fully-referenced information on medicines, vitamins, herbs, and dietary and lifestyle changes that may be helpful.
If untreated, high levels of phenylalanine can cause severe mental retardation, behavioral disturbances, and other brain and nerve problems. Fortunately, newborn screening programs now identify most cases of PKU in the United States and other countries. Early diagnosis and treatment is the key to reducing or preventing PKU-related conditions.2 Gene therapy is currently being researched as a possible cure.3 4 Research is also being conducted on methods to decrease levels of phenylalanine in the blood through the use of certain enzymes5 and amino acids.6
Product ratings for phenylketonuria
|Science Ratings||Nutritional Supplements||Herbs|
Branched-chain amino acids (BCAA)
Fish oil (if PUFA deficient)
L-tyrosine (if deficient)
Selenium (if deficient)
Vitamin B12 (if deficient)
Vitamin K (if deficient)
Reliable and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support and/or minimal health benefit.
Infants with PKU may be lethargic, feed poorly, and have a “mousy” odor from their sweat and urine. Eczema, sensitivity to sunlight, and light skin are also characteristic of PKU. Symptoms of children with untreated PKU include significantly diminished mental capacity, hyperactivity, and seizures.
PKU can be controlled by a diet low in phenylalanine.7 The greatest benefits are achieved when the diet is started in the first few days of life,8 although later treatment will still help to reduce the severity of PKU-related conditions.9 10 11 Maintaining low phenylalanine levels through dietary control improves muscle control and behavioral and intellectual function.12 13
The effects of elevated phenylalanine appear to be less severe in older children and adults than in newborns and young children, in whom the nervous system is still developing. This, combined with the difficulties inherent in following a strict lifelong diet, have caused researchers to examine whether the dietary regimen may be relaxed as children get older. While some research suggests that relaxation of dietary measures may not be harmful,14 15 16 this has not been found to be true in all studies.17 Therefore, more research is needed to resolve this issue.18 19 In a survey of 111 PKU treatment centers, 87% favored lifelong dietary restriction of phenylalanine.20 The PKU diet is strict, and should be undertaken with the help of a nutritionist and a physician.
Breast-feeding, as opposed to formula feeding, appears to confer some benefits in children born with PKU who were not treated until 20–40 days of age. In a preliminary study, children with PKU who had been breast-fed rather than formula fed prior to receiving dietary treatment scored significantly higher on IQ testing.21 Infants with PKU tend to retain abnormal amounts of the trace mineral molybdenum. Since infant formulas are supplemented with amounts of molybdenum that far exceed amounts found in breast milk, infants with PKU who are also fed formula run the risk of accumulating excessive molybdenum.22
A PKU diet is low in protein, providing no more than the minimum amount of phenylalanine needed by the body. All high-protein foods, such as dairy products, eggs, fish, meats, poultry, legumes, and nuts, are usually eliminated.23 Lower protein foods, such as fruits, vegetables and some grain products, are allowed in measured amounts, along with specially prepared phenylalanine-free or nearly phenylalanine-free foods. This diet is supplemented with an amino acid formula to increase protein intake without adding more phenylalanine than is nutritionally required.
Phenylalanine levels fluctuate as a consequence of changes in diet, health, and growth; therefore, levels must be checked regularly.24 A nutrition specialist can also provide information on homemade and specially prepared foods for people with PKU, including infant formulas, low protein pastas, breads, crackers, and other foods.
People with PKU who are not following the PKU diet can become deficient in biotin, a water-soluble B vitamin. This is because phenylalanine blocks biotin metabolism. In a controlled study of children with PKU, elevated phenylalanine levels resulted in seborrheic dermatitis caused by biotin deficiency, which was corrected by a return to the phenylalanine-restricted diet.25
There is debate about whether it is safe for people with PKU to consume aspartame, a low-calorie sweetener that contains about 50% phenylalanine. In one study, blood levels of phenylalanine increased only slightly after people with PKU ingested a 12-ounce soft drink sweetened with aspartame.26 However, that study did not address long-term effects of regular aspartame consumption. Until more is known, it is prudent for people with PKU to completely avoid aspartame-containing beverages and foods.
Access to PKU resource/support groups, and education of family members may help simplify the complex dietary restrictions and improve one’s ability to follow them.27 28 29
PKU during pregnancy (maternal PKU) is of particular concern. Excessively high or low levels of phenylalanine may occur during pregnancy, both of which may adversely affect the fetus.30 Maternal PKU can lead to fetal malformations, including small head size (microcephaly), heart abnormalities, failure to grow properly in the uterus (called intrauterine growth retardation), and mental retardation.31 Adverse effects on the offspring can be reduced and by careful dietary control both prior to and during pregnancy.32 33 34 Consultation and follow-up visits with medical and nutritional specialists are necessary for effective monitoring and dietary guidance in people with PKU.
Other treatment consists of strict adherence to a diet low in phenylalanine, in order to prevent a buildup of phenylalanine in the body.
Because of the importance of strict dietary control, nutritional supplementation should be supervised by a specialist.
In a double-blind trial, regular use of branched-chain amino acids (BCAAs) (i.e., valine, isoleucine, and leucine) by adolescents and young adults with PKU improved performance on some tests of mental functioning.35 Participants received either placebo, or 150 mg per 2.2 pounds of body weight each of valine and isoleucine, and 200 mg per 2.2 pounds of body of leucine, taken with meals and at bedtime. Participants received one mixture or the other for four three-month periods, for a total of six months’ supplementation of each regimen over the course of a year.
PKU results from a deficiency or malfunction of the enzyme, phenylalanine hydroxylase, which converts phenylalanine to L-tyrosine.36 People with PKU have elevated concentrations of phenylalanine and low levels of L-tyrosine,37 which may contribute to behavior problems.38 39 In addition, low L-tyrosine levels in pregnant women with PKU may contribute to fetal damage.40 In some,41 but not all,42 double-blind studies, keeping L-tyrosine levels in the normal range by adding supplemental L-tyrosine to the diet improved behavior. In a preliminary study, blood L-tyrosine levels fluctuated significantly in people with PKU, suggesting a need for careful laboratory monitoring of people supplementing with L-tyrosine.43
The PKU diet is low in fatty acids, some of which are essential for proper brain development.44 In one controlled study of children with PKU who were deficient in fatty acids, supplementation with fish oil (but not with black currant seed oil) for six months improved the deficiency. The children received 500 mg of oil per 8.8 pounds of body weight each day for 6 months. The amount varied from 5–8 capsules (each containing 500 mg) per day for each child.45 In another study, fish oil supplementation (providing 15 mg of docosahexaenoic acid per 2.2 pounds of body weight per day) improved body coordination and fine motor skills in children with PKU.46
People with PKU may be deficient in several nutrients, due to the restricted diet which is low in protein and animal fat. Deficiencies of long-chain polyunsaturated fatty acids (LC-PUFAs),47 48 49 selenium,50 51 52 53 vitamin B12,54 and vitamin K may develop on this diet.55
Selenium is important for normal antioxidant function. Research suggests that selenium deficiency and decreased antioxidant activity may contribute to the brain and nerve disorders associated with PKU.56 In two preliminary studies involving selenium-deficient people with PKU, supplementation with selenium in the form of sodium selenite corrected the deficiency,57 whereas supplementation with selenium in the form of selenomethionine did not.58
Vitamin B12 is found almost exclusively in foods of animal origin, which are restricted on the PKU diet. People on the PKU diet who are inconsistent in their use of a vitamin B12 supplement may become deficient in this vitamin. In a survey of young adults with PKU, 32% were found to have low or low-normal blood levels of vitamin B12.59 Vitamin B12 deficiency can cause anemia and nerve problems.
Because the PKU diet is low in animal products, fat intake is also significantly reduced. The results of a preliminary study of children with PKU suggested that the low-fat PKU diet intake may impair the absorption of vitamin K, a fat-soluble vitamin, from the diet, possibly resulting in a vitamin K deficiency. In that study, children with PKU on a strict diet had low levels of certain vitamin K-dependent proteins needed for normal blood clotting.60
1. Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philos Trans R Soc Lond B Biol Sci 1996;351:1483–93 [review].
2. Cabalska MB, Nowaczewska I, Sendecka E, Zorska K. Longitudinal study on early diagnosis and treatment of phenylketonuria in Poland. Eur J Pediatr 1996;155 Suppl 1:S53–5.
3. Eisensmith RC, Woo SL. Gene therapy for phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S16–9 [review].
4. Lin CM, Tan Y, Lee YM, et al. Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. J Inherit Metab Dis 1997;20:742–54.
5. Sarkissian CN, Shao Z, Blain F, et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci 1999;96:2339–44.
6. Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 1999;103:1169–78.
7. Diamond A. Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philos Trans R Soc Lond B Biol Sci 1996;351:1483–93 [review].
8. Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. Eur J Pediatr 1996;155 Suppl 1:S125–9.
9. Koch R, Moseley K, Ning J, et al. Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. Mol Genet Metab 1999;67:148–55.
10. Yannicelli S, Ryan A. Improvements in behavior and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey. J Inherit Metab Dis 1995;18:131–4.
11. Williams K. Benefits of normalizing plasma phenylalanine: impact on behavior and health. A case report. J Inherit Metab Dis 1998;21:785–90.
12. Arnold G, Kramer BM, Kirby RS, et al. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. Acta Paediatr 1998;87:565–70.
13. Baumeister AA, Baumeister AA. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. Clin Neuropharmacol 1998;21:18–27 [review].
14. Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. J Inherit Metab Dis 1998;21:29–38.
15. Griffiths P, Smith C, Harvie A. Transitory hyperphenylalaninaemia in children with continuously treated phenylketonuria. Am J Ment Retard 1997;102:27–36.
16. Cerone R, Schiaffino MC, Di Stefano S, Veneselli E. Phenylketonuria: diet for life or not? Acta Paediatrica 1999;88:664–6.
17. Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 1997;62:1–208.
18. Griffiths P, Ward N, Harvie A, Cockburn F. Neuropsychological outcome of experimental manipulation of phenylalanine intake in treated phenylketonuria. J Inherit Metab Dis 1998;21:29–38.
19. Ullrich K. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr 1999;158:46–54.
20. Fisch RO, Matalon R, Weisberg S, Michals K. Phenylketonuria: current dietary treatment practices in the United States and Canada. J Am Coll Nutr 1997;16:147–51.
21. Riva E, Agostoni C, Biasucci G, et al. Early breastfeeding is linked to higher intelligence quotient scores in dietary treated phenylketonuric children. Acta Paediatr 1996;85:56–8.
22. Sievers E, Arpe T, Schleyerbach U, Schaub J. Molybdenum supplementation in phenylketonuria diets: adequate in early infancy? J Pediatr Gastroenterol Nutr 2000;31:57–62.
23. Start K. Treating phenylketonuria by a phenylalanine-free diet. Prof Care Mother Child 1998;8:109–10 [review].
24. Davidson PW. Factors affecting cognitive, motor, behavioral and executive functioning in children with phenylketonuria. Acta Paediatr 1998;87:565–70.
25. Schulpis KH, Nyalala JO, Papakonstantinou ED, et al. Biotin recycling impairment in phenylketonuric children with seborrheic dermatitis. Int J Dermatol 1998;37:918–21.
26. Mackey SA, Berlin CM Jr. Effect of dietary aspartame on plasma concentrations of phenylalanine and tyrosine in normal and homozygous phenylketonuric patients. Clin Pediatr 1992;31:394–9.
27. Waisbren SE, Rokni H, Bailey I, et al. Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp. J Inherit Metab Dis 1997;20:21–7.
28. Scheibenreiter S, Tiefenthaler M, Hinteregger V, et al. Austrian report on longitudinal outcome in phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S45–9.
29. Weglage J, Funders B, Ullrich K, et al. Psychosocial aspects in phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S101–4.
30. Brenton DP, Lilburn M. Maternal phenylketonuria. A study from the United Kingdom. Eur J Pediatr 1996;155 Suppl 1:S177–80.
31. Levy HL, Ghavami M. Maternal phenylketonuria: a metabolic teratogen. Teratology 1996;53:176–84 [review].
32. Cechak P, Hejcmanova L, Rupp A. Long-term follow-up of patients treated for phenylketonuria (PKU). Results from the Prague PKU Center. Eur J Pediatr 1996;155 Suppl 1:S59–63.
33. Cipcic-Schmidt S, Trefz FK, Funders B, et al. German Maternal Phenylketonuria Study. Eur J Pediatr 1996;155 Suppl 1:S173–6.
34. Rouse B, Azen C, Koch R, et al. Maternal Phenylketonuria Collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 1997;69:89–95.
35. Berry HK, Brunner RL, Hunt MM, et al. Valine, isoleucine, and leucine. A new treatment for phenylketonuria. Am J Dis Child 1990;144:539–43.
36. Pietz J. Neurological aspects of adult phenylketonuria. Curr Opin Neurol 1998;11:679–88 [review].
37. van Spronsen FJ, van Dijk T, Smit GP, et al. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr 1996;64:916–21.
38. Smith ML, Hanley WB, Clarke JT, et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch Dis Child 1998;78:116–21.
39. Tam SY, Roth RH. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Biochem Pharmacol 1997;53:441–53 [review].
40. Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal phenylketonuria. Am J Clin Nutr 1998;67:473–6.
41. Wasser S, Ettrich KU, Schmidt KD, et al. Case studies of the effect of tyrosine administration in children with phenylketonuria on cognitive processes. Klin Padiatr 1992;204:417–21 [in German].
42. Smith ML, Hanley WB, Clarke JT, et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Arch Dis Child 1998;78:116–21.
43. van Spronsen FJ, van Dijk T, Smit GP, et al. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr 1996;64:916–21.
44. Giovannini M, Agostoni C, Biasucci G, et al. Fatty acid metabolism in phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S132–5.
45. Agostoni C, Riva E, Biasucci G, et al. The effects of n-3 and n-6 polyunsaturated fatty acids on plasma lipids and fatty acids of treated phenylketonuric children. Prostaglandins Leukot Essent Fatty Acids 1995;53:401–4.
46. Beblo S, Reinhardt H, Demmelmair H, et al. Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J Pediatr 2007;150:479–84.
47. Agostoni C, Marangoni F, Riva E, et al. Plasma arachidonic acid and serum thromboxane B2 concentrations in phenylketonuric children negatively correlate with dietary compliance. Prostaglandins Leukot Essent Fatty Acids 1997;56:219–22.
48. Giovannini M, Agostoni C, Biasucci G, et al. Fatty acid metabolism in phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S132–5.
49. Poge AP, Baumann K, Muller E, et al. Long-chain polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of children with phenylketonuria after controlled linoleic acid intake. J Inherit Metab Dis 1998;21:373–81.
50. Jochum F, Terwolbeck K, Meinhold H, et al. Effects of a low selenium state in patients with phenylketonuria. Acta Paediatr 1997;86:775–7.
51. Kauf E, Seidel J, Winnefeld K, et al. Selenium in phenylketonuria patients. Effects of sodium selenite administration. Med Klin 1997;92 Suppl 3:31–4 [in German].
52. Sierra C, Vilaseca MA, Moyano D, et al. Antioxidant status in hyperphenylalaninemia. Clin Chim Acta 1998;276:1–9.
53. Gropper SS, Naglak MC, Nardella M, et al. Nutrient intakes of adolescents with phenylketonuria and infants and children with maple syrup urine disease on semisynthetic diets. J Am Coll Nutr 1993;12:108–14.
54. Hanley WB, Feigenbaum AS, Clarke JT, et al. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S145–7.
55. Schulpis KH, Platokouki H, Papakonstantinou ED, et al. Haemostatic variables in phenylketonuric children under dietary treatment. J Inherit Metab Dis 1996;19:603–9.
56. Sierra C, Vilaseca MA, Moyano D, et al. Antioxidant status in hyperphenylalaninemia. Clin Chim Acta 1998;276:1–9.
57. Kauf E, Seidel J, Winnefeld K, et al. Selenium in phenylketonuria patients. Effects of sodium selenite administration. Med Klin 1997;92 Suppl 3:31–4 [in German].
58. Lombeck I, Jochum F, Terwolbeck K. Selenium status in infants and children with phenylketonuria and in maternal phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S140–4.
59. Hanley WB, Feigenbaum AS, Clarke JT, et al. Vitamin B12 deficiency in adolescents and young adults with phenylketonuria. Eur J Pediatr 1996;155 Suppl 1:S145–7.
60. Schulpis KH, Platokouki H, Papakonstantinou ED, et al. Haemostatic variables in phenylketonuric children under dietary treatment. J Inherit Metab Dis 1996;19:603–9.
Copyright © 2007 Healthnotes, Inc. All rights reserved. www.healthnotes.com
The information presented in Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires September 2008.